Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4609]

Toward the first drug to treat a rare, lethal liver cancer

Toward the first drug to treat a rare, lethal liver cancer

Model suggests surgery should precede chemotherapy for select patients with ovarian cancer

Model suggests surgery should precede chemotherapy for select patients with ovarian cancer

New theranostic approach joins radiopharmaceuticals and nanoparticles to kill cancer cells

New theranostic approach joins radiopharmaceuticals and nanoparticles to kill cancer cells

NICE approves first immunotherapy combination for advanced bowel cancer patients with rare MSI-H/dMMR mutation

NICE approves first immunotherapy combination for advanced bowel cancer patients with rare MSI-H/dMMR mutation

EHA 2021: First-line ibrutinib + venetoclax is superior to chlorambucil + obinutuzumab for chronic lymphocytic leukaemia/small lymphocyte lymphoma

EHA 2021: First-line ibrutinib + venetoclax is superior to chlorambucil + obinutuzumab for chronic lymphocytic...

EHA 2021: Overall survival benefit established with daratumumab plus lenalidomide and dexamethasone in elderly patients with transplant-ineligible newly diagnosed multiple myeloma

EHA 2021: Overall survival benefit established with daratumumab plus lenalidomide and dexamethasone in elderly...

An omega-3 that's poison for tumours

An omega-3 that's poison for tumours

Promising ovarian cancer treatment proves effective and efficient

Promising ovarian cancer treatment proves effective and efficient

EHA 2021: ALPINE study reveals superior safety and efficacy of zanubrutinib compared with ibrutinib

EHA 2021: ALPINE study reveals superior safety and efficacy of zanubrutinib compared with ibrutinib

Study sheds light on treatment options for devastating childhood brain cancer

Study sheds light on treatment options for devastating childhood brain cancer

More from ecancer